Mostrar el registro sencillo del ítem
Coumarins and adenosine receptors: New perceptions in structure–affinity relationships
dc.contributor.author | Fonseca A. | |
dc.contributor.author | Matos M.J. | |
dc.contributor.author | Vilar S. | |
dc.contributor.author | Kachler S. | |
dc.contributor.author | Klotz K.-N. | |
dc.contributor.author | Uriarte E. | |
dc.contributor.author | Borges F. | |
dc.date.accessioned | 2020-09-02T22:17:54Z | |
dc.date.available | 2020-09-02T22:17:54Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1111/cbdd.13075 | |
dc.identifier.citation | 91, 1, 245-256 | |
dc.identifier.issn | 17470277 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/4496 | |
dc.description | Adenosine receptor (AR) subtypes are involved in several physiological and pharmacological processes. Ligands that are able to selectively modulate one receptor subtype can delay or slow down the progression of diverse diseases. In this context, our research group focused its investigation into the discovery and development of novel, potent and selective AR ligands based on coumarin scaffold. Therefore, a series of 3-phenylcarboxamidocoumarins were synthesized and their affinity for the human AR subtypes was screened by radioligand binding assays for A 1 , A 2A and A 3 receptors and for A 2B by adenylyl cyclase assay. Compound 26 was found to be the most remarkable, with a hA 1 /hA 3 and hA 2A /hA 3 selectivity of 42, for the A 3 AR (K i = 2.4 μm). Receptor-driven molecular modelling studies have provided valuable information on the binding/selectivity data of compound 26 and for the following optimization process. Moreover, compound 26 presents drug-like properties according to the general guidelines linked to the concept. © 2017 John Wiley & Sons A/S. | |
dc.language.iso | en | |
dc.publisher | Blackwell Publishing Ltd | |
dc.subject | adenosine receptors | |
dc.subject | carboxamidocoumarin | |
dc.subject | coumarins | |
dc.subject | 3 phenylcarboxamidocoumarin derivative | |
dc.subject | adenosine receptor | |
dc.subject | adenylate cyclase | |
dc.subject | coumarin derivative | |
dc.subject | n (2 bromophenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (2 bromophenyl)coumarin 3 carboxamide | |
dc.subject | n (2 chlorophenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (2 chlorophenyl) 6 methylcoumarin 3 carboxamide | |
dc.subject | n (2 chlorophenyl)coumarin 3 carboxamide | |
dc.subject | n (2 hydroxyphenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (2 hydroxyphenyl)coumarin 3 carboxamide | |
dc.subject | n (2 methoxyphenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (2 methoxyphenyl)coumarin 3 carboxamide | |
dc.subject | n (2 methylphenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (2 methylphenyl)coumarin 3 carboxamide | |
dc.subject | n (3 bromophenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (3 bromophenyl)coumarin 3 carboxamide | |
dc.subject | n (3 chlorophenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (3 chlorophenyl) 6 methylcoumarin 3 carboxamide | |
dc.subject | n (3 chlorophenyl)coumarin 3 carboxamide | |
dc.subject | n (3 hydroxyphenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (3 hydroxyphenyl)coumarin 3 carboxamide | |
dc.subject | n (3 methoxyphenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (3 methoxyphenyl)coumarin 3 carboxamide | |
dc.subject | n (3 methylphenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (3 methylphenyl)coumarin 3 carboxamide | |
dc.subject | n (4 hydroxyphenyl) 6 methoxycoumarin 3 carboxamide | |
dc.subject | n (4 hydroxyphenyl)coumarin 3 carboxamide | |
dc.subject | n (4 methylphenyl)coumarin 3 carboxamide | |
dc.subject | unclassified drug | |
dc.subject | unindexed drug | |
dc.subject | adenosine receptor | |
dc.subject | coumarin derivative | |
dc.subject | isoprotein | |
dc.subject | ligand | |
dc.subject | Article | |
dc.subject | binding affinity | |
dc.subject | drug receptor binding | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | human | |
dc.subject | molecular docking | |
dc.subject | molecular model | |
dc.subject | priority journal | |
dc.subject | process optimization | |
dc.subject | structure analysis | |
dc.subject | binding site | |
dc.subject | chemistry | |
dc.subject | drug design | |
dc.subject | metabolism | |
dc.subject | protein tertiary structure | |
dc.subject | radioassay | |
dc.subject | structure activity relation | |
dc.subject | Binding Sites | |
dc.subject | Coumarins | |
dc.subject | Drug Design | |
dc.subject | Humans | |
dc.subject | Ligands | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Protein Isoforms | |
dc.subject | Protein Structure, Tertiary | |
dc.subject | Radioligand Assay | |
dc.subject | Receptors, Purinergic P1 | |
dc.subject | Structure-Activity Relationship | |
dc.title | Coumarins and adenosine receptors: New perceptions in structure–affinity relationships | |
dc.type | Article |